Cognitive performance and lifetime cannabis use in patients with first-episode schizophrenia spectrum disorder

References

• Awad, A. G., & Voruganti, L. L. N. P. (2015). Revisiting the “self-medication” hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior. Therapeutic Advances in Psychopharmacology, 5(3), 172–178. https://doi.org/10.1177/2045125315583820
   PubMed Web of Science ®Google Scholar
• Bora, E., & Pantelis, C. (2015). Meta-analysis of cognitive impairment in first-episode bipolar disorder: Comparison with first-episode schizophrenia and healthy controls. Schizophrenia Bulletin, 41(5), 1095–1104. https://doi.org/10.1093/schbul/sbu198
   PubMed Web of Science ®Google Scholar
• Broyd, S. J., van Hell, H. H., Beale, C., Yücel, M., & Solowij, N. (2016). Acute and chronic effects of cannabinoids on human cognition – a systematic review. Biological Psychiatry, 79(7), 557–567. https://doi.org/10.1016/j.biopsych.2015.12.002
   PubMed Web of Science ®Google Scholar
• Castellanos-Ryan, N., Pingault, J. B., Parent, S., Vitaro, F., Tremblay, R. E., & Seguin, J. R. (2017). Adolescent cannabis use, change in neurocognitive function, and high-school graduation: A longitudinal study from early adolescence to young adulthood. Development and Psychopathology, 29(4), 1253–1266. https://doi.org/10.1017/S0954579416001280
   PubMed Web of Science ®Google Scholar
• Chambers, R. A., Krystal, J. H., & Self, D. W. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50(2), 71–83. https://doi.org/10.1016/S0006-3223(01)01134-9
   PubMed Web of Science ®Google Scholar
• Chang, L., Yakupov, R., Cloak, C., & Ernst, T. (2006). Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain: a Journal of Neurology, 129(Pt 5), 1096–1112. https://doi.org/10.1093/brain/awl064
   PubMedGoogle Scholar
• Chong, S. A., Subramaniam, M., Lee, I. M., Pek, E., Cheok, C., Verma, S., & Wong, J. (2009). Academic attainment: A predictor of psychiatric disorders? Social Psychiatry and Psychiatric Epidemiology, 44(11), 999. https://doi.org/10.1007/s00127-009-0027-3
   PubMed Web of Science ®Google Scholar
• Cunha, P. J., Rosa, P. G., Ayres, A., Duran, F. L., Santos, L. C., Scazufca, M., Menezes, P. R., dos Santos, B., Murray, R. M., Crippa, J. A., Busatto, G. F., & Schaufelberger, M. S. (2013). Cannabis use, cognition and brain structure in first-episode psychosis. Schizophrenia Research, 147(2–3), 209–215. https://doi.org/10.1016/j.schres.2013.04.009
   PubMed Web of Science ®Google Scholar
• de la Serna, E., Mayoral, M., Baeza, I., Arango, C., Andrés, P., Bombin, I., González, C., Rapado, M., Robles, O., Rodríguez-Sánchez, J. M., Zabala, A., & Castro-Fornieles, J. (2010). Cognitive functioning in children and adolescents in their first episode of psychosis: Differences between previous cannabis users and nonusers. The Journal of Nervous and Mental Disease, 198(2), 159–162. https://doi.org/10.1097/NMD.0b013e3181cc0d41
   PubMed Web of Science ®Google Scholar
• Dervaux, A., Laqueille, X., Bourdel, M. C., Leborgne, M. H., Olié, J. P., Lôo, H., & Krebs, M. O. (2003). Cannabis et schizophrénie: données cliniques et socio-démographiques [Cannabis and schizophrenia: Demographic and clinical correlates]. L'Encephale, 29(1), 11–17.
   PubMed Web of Science ®Google Scholar
• Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., Butt, A., Stilo, S. A., Wiffen, B., Powell, J., & Murray, R. M. (2009). High-potency cannabis and the risk of psychosis. The British Journal of Psychiatry, 195(6), 488–491. https://doi.org/10.1192/bjp.bp.109.064220
   PubMed Web of Science ®Google Scholar
• Gage, S. H., Hickman, M., & Zammit, S. (2016). Association Between cannabis and psychosis: Epidemiologic evidence. Biological Psychiatry, 79(7), 549–556. https://doi.org/10.1016/j.biopsych.2015.08.001
   PubMed Web of Science ®Google Scholar
• Galderisi, S., Rossi, A., Rocca, P., Bertolino, A., Mucci, A., Bucci, P., Rucci, P., Gibertoni, D., Aguglia, E., Amore, M., Blasi, G., Comparelli, A., Di Giannantonio, M., Goracci, A., Marchesi, C., Monteleone, P., Montemagni, C., Pinna, F., Roncone, R., Siracusano, A., … Italian Network for Research on Psychoses. (2016). Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophrenia Research, 175(1–3), 154–160. https://doi.org/10.1016/j.schres.2016.04.043
   PubMed Web of Science ®Google Scholar
• Ganzer, F., Broening, S., Kraft, S., Sack, P. M., & Thomasius, R. (2016). Weighing the evidence: A systematic review on long-term neurocognitive effects of cannabis use in abstinent adolescents and adults. Neuropsychology Review, 26(2), 186–222. https://doi.org/10.1007/s11065-016-9316-2
   PubMed Web of Science ®Google Scholar
• Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010). International consensus study of antipsychotic dosing. The American Journal of Psychiatry, 167(6), 686–693. https://doi.org/10.1176/appi.ajp.2009.09060802
   PubMed Web of Science ®Google Scholar
• Gonzalez, R., Pacheco-Colón, I., Duperrouzel, J. C., & Hawes, S. W. (2017). Does cannabis use cause declines in neuropsychological functioning? A review of longitudinal studies. Journal of the International Neuropsychological Society, 23(9-10), 893–902. https://doi.org/10.1017/S1355617717000789
   PubMed Web of Science ®Google Scholar
• Grace, A. A. (2016). Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nature Reviews. Neuroscience, 17(8), 524–532. https://doi.org/10.1038/nrn.2016.57
   PubMed Web of Science ®Google Scholar
• Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? The American Journal of Psychiatry, 153(3), 321–330. https://doi.org/10.1176/ajp.153.3.321
   PubMed Web of Science ®Google Scholar
• Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42(4), 327–360. https://doi.org/10.2165/00003088-200342040-00003
   PubMed Web of Science ®Google Scholar
• Hall, W., & Degenhardt, L. (2014). The adverse health effects of chronic cannabis use. Drug Testing and Analysis, 6(1-2), 39–45. https://doi.org/10.1002/dta.1506
   PubMed Web of Science ®Google Scholar
• Hanna, R. C., Shalvoy, A., Cullum, C. M., Ivleva, E. I., Keshavan, M., Pearlson, G., Hill, S. K., Sweeney, J. A., Tamminga, C. A., & Ghose, S. (2016). Cognitive function in individuals with psychosis: Moderation by adolescent cannabis Use. Schizophrenia Bulletin, 42(6), 1496–1503. https://doi.org/10.1093/schbul/sbw030
   PubMed Web of Science ®Google Scholar
• Hart, C. L., Ilan, A. B., Gevins, A., Gunderson, E. W., Role, K., Colley, J., & Foltin, R. W. (2010). Neurophysiological and cognitive effects of smoked marijuana in frequent users. Pharmacology, Biochemistry, and Behavior, 96(3), 333–341. https://doi.org/10.1016/j.pbb.2010.06.003
   PubMed Web of Science ®Google Scholar
• Heinrichs, R. W., & Zakzanis, K. K. (1998). Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology, 12(3), 426–445. https://doi.org/10.1037/0894-4105.12.3.426
   PubMed Web of Science ®Google Scholar
• Helle, S., Løberg, E. M., Gjestad, R., Schnakenberg Martin, A. M., & Lysaker, P. H. (2017). The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry Research, 250, 92–98. https://doi.org/10.1016/j.psychres.2017.01.047
   PubMed Web of Science ®Google Scholar
• Hunault, C. C., Mensinga, T. T., Böcker, K. B., Schipper, C. M., Kruidenier, M., Leenders, M. E., de Vries, I., & Meulenbelt, J. (2009). Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology, 204(1), 85–94. https://doi.org/10.1007/s00213-008-1440-0
   PubMed Web of Science ®Google Scholar
• Hunt, G. E., Large, M. M., Cleary, M., Lai, H. M. X., & Saunders, J. B. (2018). Prevalence of Comorbid Substance use in Schizophrenia Spectrum Disorders in Community and Clinical Settings, 1990-2017: Systematic review and meta-analysis. Drug and Alcohol Dependence, 191, 234–258. https://doi.org/10.1016/j.drugalcdep.2018.07.011
   PubMed Web of Science ®Google Scholar
• Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. http://doi.org/10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Kelley, M. E., Wan, C. R., Broussard, B., Crisafio, A., Cristofaro, S., Johnson, S., Reed, T. A., Amar, P., Kaslow, N. J., Walker, E. F., & Compton, M. T. (2016). Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophrenia Research, 171(1–3), 62–67. https://doi.org/10.1016/j.schres.2016.01.015
   PubMed Web of Science ®Google Scholar
• Khokhar, J. Y., Dwiel, L. L., Henricks, A. M., Doucette, W. T., & Green, A. I. (2018). The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophrenia Research, 194, 78–85. https://doi.org/10.1016/j.schres.2017.04.016
   PubMed Web of Science ®Google Scholar
• Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophrenia Bulletin. 36(6) 1115–1130. https://doi.org/10.1093/schbul/sbp031
   PubMed Web of Science ®Google Scholar
• Larsen, T. K., Friis, S., Haahr, U., Johannessen, J. O., Melle, I., Opjordsmoen, S., Rund, B. R., Simonsen, E., Vaglum, P. V., & McGlashan, T. H. (2004). Premorbid adjustment in first-episode non-affective psychosis: Distinct patterns of pre-onset course. The British Journal of Psychiatry: the Journal of Mental Science, 185(2), 108–115. https://doi.org/10.1192/bjp.185.2.108
   PubMedGoogle Scholar
• Løberg, E.-M., Helle, S., Nygård, M., Berle, JØ, Kroken, R. A., & Johnsen, E. (2014). The cannabis pathway to non-affective psychosis may reflect less neurobiological vulnerability. Frontiers in Psychiatry, 5, https://doi.org/10.3389/fpsyt.2014.00159
   Google Scholar
• Løberg, E. M., & Hugdahl, K. 2009. Cannabis use and cognition in schizophrenia. Frontiers in Human Neuroscience, 3, 53. https://doi.org/10.3389/neuro.09.053.2009
   PubMed Web of Science ®Google Scholar
• Lorenzetti, V., Solowij, N., Fornito, A., Ian Lubman, D., & Yucel, M. (2014). The association between regular cannabis exposure and alterations of human brain morphology: An updated review of the literature. Current Pharmaceutical Design, 20(13), 2138–2167. https://doi.org/10.2174/13816128113199990435
   PubMed Web of Science ®Google Scholar
• Lovell, M. E., Akhurst, J., Padgett, C., Garry, M. I., & Matthews, A. (2020). Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: A meta-analysis. Experimental and Clinical Psychopharmacology, 28(4), 471–494. https://doi.org/10.1037/pha0000326
   PubMed Web of Science ®Google Scholar
• Maia, T. V., & Frank, M. J. (2017). An integrative perspective on the role of dopamine in schizophrenia. Biological Psychiatry, 81(1), 52–66. https://doi.org/10.1016/j.biopsych.2016.05.021
   PubMed Web of Science ®Google Scholar
• Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269. https://doi.org/10.1093/schbul/sbw003
   PubMed Web of Science ®Google Scholar
• Mata, I., Rodriguez-Sanchez, J. M., Pelayo-Teran, J. M., Perez-Iglesias, R., Gonzalez-Blanch, C., Ramirez-Bonilla, M., Martínez-García, O., Vázquez-Barquero, J. L., & Crespo-Facorro, B. (2008). Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychological Medicine, 38(9), 1257. https://doi.org/10.1017/S0033291707002218
   PubMed Web of Science ®Google Scholar
• Menendez-Miranda, I., Garcia-Alvarez, L., Garcia-Portilla, M. P., Gonzalez-Blanco, L., Saiz, P. A., & Bobes, J. (2019). History of lifetime cannabis use is associated with better cognition and worse real-world functioning in schizophrenia spectrum disorders. European Addiction Research, 25(3), 111–118. https://doi.org/10.1159/000497317
   PubMed Web of Science ®Google Scholar
• Meyers, J. E., & Meyers, K. R. (1995). Rey complex figure test under four different administration procedures. Clinical Neuropsychologist, 9(1), 63–67. https://doi.org/10.1080/13854049508402059
   Google Scholar
• Mokrysz, C., Landy, R., Gage, S. H., Munafò, M. R., Roiser, J. P., & Curran, H. V. (2016). Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. Journal of Psychopharmacology, 30(2), 159–168. https://doi.org/10.1177/0269881115622241
   PubMed Web of Science ®Google Scholar
• Morrison, P. D., Nottage, J., Stone, J. M., Bhattacharyya, S., Tunstall, N., Brenneisen, R., Holt, D., Wilson, D., Sumich, A., McGuire, P., Murray, R. M., Kapur, S., & Ffytche, D. H. (2011). Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 36(4), 827–836. https://doi.org/10.1038/npp.2010.222
   PubMed Web of Science ®Google Scholar
• Musshoff, F., & Madea, B. (2006). Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Therapeutic Drug Monitoring, 28(2), 155–163. https://doi.org/10.1097/01.ftd.0000197091.07807.22
   PubMed Web of Science ®Google Scholar
• Nesvåg, R., Knudsen, G. P., Bakken, I. J., Høye, A., Ystrom, E., Surén, P., Reneflot, A., Stoltenberg, C., &  Reichborn-Kjennerud, T. (2015). Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: A registry-based study. Social Psychiatry and Psychiatric Epidemiology, 50(8), 1267–1276. https://doi.org/10.1007/s00127-015-1025-2
   PubMed Web of Science ®Google Scholar
• Nuechterlein, K. H., Barch, D. M., Gold, J. M., Goldberg, T. E., Green, M. F., & Heaton, R. K. (2004). Identification of separable cognitive factors in schizophrenia. Schizophrenia Research, 72(1), 29–39. https://doi.org/10.1016/j.schres.2004.09.007
   PubMed Web of Science ®Google Scholar
• Osborne, A. L., Solowij, N., & Weston-Green, K. (2017). A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Neuroscience & Biobehavioral Reviews, 72, 310–324. https://doi.org/10.1016/j.neubiorev.2016.11.012
   PubMed Web of Science ®Google Scholar
• Pope, H. G., Jr, Gruber, A. J., Hudson, J. I., Huestis, M. A., & Yurgelun-Todd, D. (2002). Cognitive measures in long-term cannabis users. Journal of Clinical Pharmacology, 42(S1), 41S–47S. https://doi.org/10.1002/j.1552-4604.2002.tb06002.x
   PubMedGoogle Scholar
• Potvin, S., Joyal, C. C., Pelletier, J., & Stip, E. (2008). Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis. Schizophrenia Research, 100(1–3), 242–251. https://doi.org/10.1016/j.schres.2007.04.022
   PubMed Web of Science ®Google Scholar
• Rabin, R. A., Zakzanis, K. K., & George, T. P. (2011). The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophrenia Research, 128(1–3), 111–116. https://doi.org/10.1016/j.schres.2011.02.017
   PubMed Web of Science ®Google Scholar
• Ringen, P. A., Vaskinn, A., Sundet, K., Engh, J. A., Jónsdóttir, H., Simonsen, C., Friis, S., Opjordsmoen, S., Melle, I., & Andreassen, O. A. (2010). Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychological Medicine, 40(8), 1337–1347. https://doi.org/10.1017/S0033291709991620
   PubMed Web of Science ®Google Scholar
• Rodriguez, M., Fajnerová, I., Sedláková, K., Dorazilová, A., Voráčková, V., Paštrnák, M., Jonáš, J., Prajsová, J., Kratochvílová, Z., Španiel, F. (2017). Cluster analysis and correlations between cognitive domains: Cognitive performance in a Czech sample of first episodes schizophrenia spectrum disorders – preliminary results. Psychiatrie, 21, 4–11.
   Google Scholar
• Sánchez-Gutiérrez, T., Fernandez-Castilla, B., Barbeito, S., González-Pinto, A., Becerra-García, J., & Calvo, A. (2020). Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning. European Psychiatry, 63(1), E6. https://doi.org/10.1192/j.eurpsy.2019.9
   PubMed Web of Science ®Google Scholar
• Schoeler, T., Kambeitz, J., Behlke, I., Murray, R., & Bhattacharyya, S. (2016). The effects of cannabis on memory function in users with and without a psychotic disorder: Findings from a combined meta-analysis. Psychological Medicine, 46(1), 177–188. https://doi.org/10.1017/S0033291715001646
   PubMed Web of Science ®Google Scholar
• Schoeler, T., Petros, N., Di Forti, M., Klamerus, E., Foglia, E., Murray, R., & Bhattacharyya, S. (2017). Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: A prospective analysis. The Lancet. Psychiatry, 4(8), 627–633. https://doi.org/10.1016/S2215-0366(17)30233-X
   PubMed Web of Science ®Google Scholar
• Scott, J. C., Slomiak, S. T., Jones, J. D., Rosen, A. F. G., Moore, T. M., & Gur, R. C. (2018). Association of cannabis with cognitive functioning in adolescents and young adults: A systematic review and meta-analysis. JAMA Psychiatry, 75(6), 585–595. https://doi.org/10.1001/jamapsychiatry.2018.0335
   PubMed Web of Science ®Google Scholar
• Segev, A., & Lev-Ran, S. (2012). Neurocognitive functioning and cannabis use in schizophrenia. Current Pharmaceutical Design, 18(32), 4999–5007. https://doi.org/10.2174/138161212802884799
   PubMed Web of Science ®Google Scholar
• Solowij, N., & Battisti, R. (2008). The chronic effects of cannabis on memory in humans: A review. Current Drug Abuse Reviews, 1(1), 81–98. https://doi.org/10.2174/1874473710801010081
   PubMedGoogle Scholar
• Solowij, N., & Michie, P. T. (2007). Cannabis and cognitive dysfunction: Parallels with endophenotypes of schizophrenia? Journal of Psychiatry & Neuroscience: JPN, 32(1), 30–52.
   PubMed Web of Science ®Google Scholar
• Tosato, S., Lasalvia, A., Bonetto, C., Mazzoncini, R., Cristofalo, D., De Santi, K., Bertani, M., Bissoli, S., Lazzarotto, L., Marrella, G., Lamonaca, D., Riolo, R., Gardellin, F., Urbani, A., Tansella, M., Ruggeri, M., & PICOS-VENETO Group (2013). The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the psychosis incident Cohort outcome study (PICOS). Journal of Psychiatric Research, 47(4), 438–444. https://doi.org/10.1016/j.jpsychires.2012.11.009
   PubMed Web of Science ®Google Scholar
• Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., Bloomfield, M. A., Curran, H. V., & Baler, R. (2016). Effects of cannabis Use on human behavior, including cognition, motivation, and psychosis: A review. JAMA Psychiatry, 73(3), 292–297. https://doi.org/10.1001/jamapsychiatry.2015.3278
   PubMed Web of Science ®Google Scholar
• Wu, L.-T., Blazer, D. G., Gersing, K. R., Burchett, B., Swartz, M. S., & Mannelli, P. (2013). Comorbid substance use disorders with other axis I and II mental disorders among treatment-seeking Asian Americans, native Hawaiians/Pacific islanders, and mixed-race people. Journal of Psychiatric Research, 47(12), 1940–1948. https://doi.org/10.1016/j.jpsychires.2013.08.022
   PubMed Web of Science ®Google Scholar
• Yücel, M., Bora, E., Lubman, D. I., Solowij, N., Brewer, W. J., Cotton, S. M., Conus, P., Takagi, M. J., Fornito, A., Wood, S. J., McGorry, P. D., & Pantelis, C. (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin, 38(2), 316–330. https://doi.org/10.1093/schbul/sbq079
   PubMed Web of Science ®Google Scholar
• Zehra, A., Burns, J., Liu, C. K., Manza, P., Wiers, C. E., Volkow, N. D., & Wang, G. J. (2018). Cannabis Addiction and the brain: A review. Journal of Neuroimmune Pharmacology: the Official Journal of the Society on NeuroImmune Pharmacology, 13(4), 438–452. https://doi.org/10.1007/s11481-018-9782-9
   PubMed Web of Science ®Google Scholar